Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) patients frequently develop treatment resistance to cetuximab, a monoclonal antibody against EGFR, as well as radiotherapy. Here we addressed extracellular signal-regulated kinase 1/2 (ERK1/2) regulation by cetuximab or fractionated irradiati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Chao, Muller, Marie F., Xiang, Fang, Jensen, Alexandra, Weichert, Wilko, Major, Gerald, Plinkert, Peter K., Hess, Jochen, Affolter, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374086/
https://www.ncbi.nlm.nih.gov/pubmed/32424150
http://dx.doi.org/10.1038/s41416-020-0892-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374086/
https://www.ncbi.nlm.nih.gov/pubmed/32424150
http://dx.doi.org/10.1038/s41416-020-0892-9

Ejemplares similares